A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Clinical trial NCT02113813 · COMPLETED

Trial details

NCT number: NCT02113813
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations

Start date: 2014-04-09
Primary completion: 2017-07-28
Enrollment: 133

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.